In view of the above findings, we conclude that blocking of the activation of eosinophils by targeting CD40-CD40L and ICOS-ICOSL pathways, especially manipulation of TNF-α/p38 MAPK pathways targeting eosinophils activation might be useful for the treatment of CRS with high-level eosinophils. This evidence concerns the gene CD40LG and congenital rubella syndrome.